Skip to main content
SpringerLink
Log in

Less usual indications: Mycobacterial, Brucella, Yersinia, Francisella and other infections

  • Chapter
  • First Online:
Fluoroquinolone Antibiotics

Part of the book series: Milestones in Drug Therapy ((MDT))

  • 494 Accesses

Abstract

The fluoroquinolones possess in vitro activity against several clinically important mycobacterial species, as well as desirable pharmacokinetic and pharmacodynamic characteristics. Furthermore, recent clinical trials have clarified the role of the fluoroquinolones in the treatment of mycobacterial diseases. Although currently available fluoroquinolones are not regarded as first-line agents, they remain valuable alternative agents for these indications in special circumstances.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Berning SE (2001) The role of fluoroquinolones in tuberculosis today. Drugs 61: 9–18 (A comprehensive review of how to use fluoroquinolones for tuberculosis therapy. In addition to summarizing microbiologic and pharmacokinetic data, the author addresses practical issues such as administration regimens, drug reactions, and drug interactions.)

    Article  CAS  Google Scholar 

  2. Berning SE, Madsen L, Iseman MD, Peloquin CA (1995) Long-term safety of ofloxacin and ciprofloxacin in the treatment of mycobacterial infections. Am J Respir Crit Care Med 151: 2006–2009 (Review of 7 years’ experience with ofloxacin and ciprofloxacin in 103 patients. Both agents were well tolerated.)

    Article  CAS  Google Scholar 

  3. Kennedy N, Berger L, Curram J, Fox R, Gutmann J, Kisyombe GM, Ngowi FI, Ramsay AR, Saruni AO, Sam N et al (1996) Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis. Clin Infect Dis 22: 827–833 (Among the HIV-infected patients in this randomized trial, ciprofloxacin did not have equivalent steriliz-ing activity to pyrazinamide plus ethambutol at 6 months after completion of anti-tuberculous chemotherapy.)

    Article  CAS  Google Scholar 

  4. Mohanty KC, Khamgaye TM (1993) Controlled trial of ciprofloxacin in short-term chemotherapy for pulmonary tuberculosis. Chest 104: 1194–1198 (Twenty-four months after completion of anti-tuberculous chemotherapy, a ciprofloxacin-based regimen achieved an equivalent cure rate to a rifampin-based regimen. The sample size was small in this randomized study and statistical power to detect a difference in outcome was not stated.)

    Article  CAS  Google Scholar 

  5. El-Sadr WM, Perlman DC, Matts JP, Nelson ET, Cohn DL, Salomon N, Olibrice M, Medard F, Chirgwin KD, Mildvan D et al (1998) for the Terry Beim Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG). Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Clin Infect Dis 26: 1148–1158 (In this randomized study of HIV-infected patients, levofloxacin did not enhance the sterilizing activity of the standard 4-drug, first-line treatment regimen for tuberculosis.)

    Article  CAS  Google Scholar 

  6. Yew WW, Chan CK, Chau CH, Tam CM, Leung CC, Wong PC, Lee J (2000) Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. Chest 117: 744–751 (A retrospective case series of 63 patients with multidrug-resistant tuberculosis. Cure rate was 81%. Adverse outcome was independently associated with lung cavitation, ofloxacin resistance, and poor adherence to therapy.)

    Article  CAS  Google Scholar 

  7. Tahaoglu K, Torun T, Sevim T, Atac G, Kir A, Karasulu L, Ozmen I, Kapakli N (2001) The treatment of multidrug-resistant tuberculosis in Turkey. N Engl J Med 345: 170–174 (Review of a large series of multidrug-resistant tuberculosis cases. Successful treatment, achieved in 77% of cases, was independently associated with younger age and absence of previous treatment with ofloxacin. Demonstrates that multidrug-resistant tuberculosis can be successfully treated within the resource constraints of low-income nations.)

    Article  CAS  Google Scholar 

  8. American Thoracic Society (2000) Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 161: 5221–5247 (No data support the efficacy of fluoroquinolones for treatment of latent tuberculosis infection. A pyrazinamide plus fluoroquinolone regimen may be useful for patients with latent infection due to multidrug-resistant strains.)

    Google Scholar 

  9. Horn DL, Hewlett D, Alfalla C, Peterson S, Opal SM (1994) Limited tolerance of ofloxacin and pyrazinamide prophylaxis against tuberculosis. N Engl J Med 330: 1241

    Article  CAS  Google Scholar 

  10. Ridzon R, Meador J, Maxwell R, Higgins K, Weismuller P, Onorato IM (1997) Asymptomatic hepatitis in persons who received alternative preventive therapy with pyrazinamide and ofloxacin. Clin Infect Dis 24: 1264–1265

    Article  CAS  Google Scholar 

  11. WHO (1998) Seventh Report of the WHO Expert Committee on Leprosy. World Health Organization. Tech Rep Ser 874: 1–43 (Outlines currently recommended antimicrobial regimens for leprosy. This report endorsed a single-dose multidrug regimen for treatment of single-lesion, paucibacillary leprosy.)

    Google Scholar 

  12. Single-Lesion Multicentre Trial Group (1997) Efficacy of single dose multidrug therapy for the treatment of single-lesion paucibacillary leprosy. Indian J Lepr 69: 121–129 (Describes a multi-centre, double-blind, randomized, comparative trial of the standard 6-month WHO multidrug, paucibacillary regimen vs. a single-dose regimen of rifampin plus ofloxacin plus minocycline (ROM). Among the 1381 patients who completed the study (1483 enrolled), the relapse rate was equivalent in the 2 treatment groups.)

    Google Scholar 

  13. American Thoracic Society (1997) Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am J Respir Crit Care Med 156: S1–S25 (Comprehensive review of the treatment of infections due to nontuberculous mycobacteria. Ciprofloxacin is a proven first-line agent for combination therapy of Mycobacterium fortuitum lung infection. For most other infections, the available data do not support use of fluoroquinolones as first-line therapy.)

    Google Scholar 

  14. Benson CA (1994) Treatment of disseminated disease due to Mycobacterium avium complex in patients with AIDS. Clin Infect Dis 18 Suppl 3: S237–242 (This review paper states that new macrolides (clarithromycin or azithromycin) are more potent agents against Mycobacterium avium complex disease than ciprofloxacin, which can be used as an adjunctive agent.)

    Article  Google Scholar 

  15. Shafran SD, Singer J, Zarowny DP, Phillips P, Salit I, Walmsley SL, Fong IW, Gill MJ, Rachlis AR, LaLonde RG et al (1996) A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin vs. rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group. N Engl J Med 335: 377–383 (Multicentre, randomized, comparative trial of treatments for AIDS-related Mycobacterium avium complex bacteremia. Ciprofloxacin-based regimen is inferior to a clarithromycin-based regimen.)

    CAS  Google Scholar 

  16. Hall WH (1990) Modem chemotherapy for brucellosis in humans. Rev Infect Dis 12: 1060–1099 (A comprehensive review summarizing critically and selectively the medical literature on modern chemotherapy for Brucellosis in humans.)

    Article  CAS  Google Scholar 

  17. Solera J, Martinez-Alfaro E, Espinosa A (1997) Recognition and optimum treatment of Brucellosis. Drugs 53: 245–256 (A comprehensive review of Brucellosis with emphasis on aetiology, epidemiology, clinical spectrum, diagnosis and treatment. Detailed review of in vitro, animal, and clinical studies on brucella treatment with different class of antimicrobial agents.)

    Article  CAS  Google Scholar 

  18. Solera J (2000) Treatment of human Brucellosis. J Med Liban 48: 255–263 (A comprehensive review of how different classes of antimicrobial agent could be used in the treatment of Brucellosis with guide to the treatment of human Brucellosis.)

    CAS  PubMed  Google Scholar 

  19. Trujillano-Martin I, Garcia-Sanchez E, Martinez IM, Fresnadillo MJ, Garcia-Sanchez JE, Garcia-Rodriguez JA (1999) In vitro activities of six new fluroquinolones against Brucella melitensis. Antimicrob Agents Chemother 43: 194–195 (In vitro activity of eight fluroquinolones were tested against 160 Brucella melitensis strains. Sitafloxacin was the most active fluroquinolone tested. Other fluroquinolones tested including levofloxacin, trovafloxacin, and moxifloxacin had activities similar to or slightly greater than that of ciprofloxacin.)

    Article  CAS  Google Scholar 

  20. Gracia-Rodriguez JA, Garcia-Sanchez JE, Trujillano I, Garcia-Sanchez E, Garcia Garcia MI, Fresnadillo MJ (1995) Susceptibilities of Brucella melitensis isolates to clinafloxacin and four other new fluroquinolones. Antimicrob Agents Chemother 39: 1194–1195 (In vitro activity of six fluroquinolones were tested against 120 clinical isolates of Brucella melitensis and three reference strains of the same species. Clinafloxacin was the most active compound tested. The activity of ciprofloxacin and the other four agents were less than clinafloxacin.)

    Article  Google Scholar 

  21. Shasha B, Lang R, Rubinstein E (1992) Therapy of Experimental Murine Brucellosis with streptomycin, co-trimoxazole, ciprofloxacin, ofloxacin, pefloxacin, doxycycline, and rifampin. Antimicrob Agents Chemother 36: 973–976 (Brucella infected mice were treated with streptomycin, co-trimoxazole, ciprofloxacin, doxycycline, and rifampin intraperitoneally and with ciprofloxacin, ofloxacin, pefloxacin, doxycycline, and rifampin orally for 14 to 21 days. Therapy failure was noted in all mice treated with ciprofloxacin, ofloxacin, and pefloxacin administered orally as well as in mice treated intraperitoneally with ciprofloxacin.)

    Article  CAS  Google Scholar 

  22. Lang R, Shasha B, Rubinstein E (1993) Therapy of experimental Murine brucellosis with streptomycin alone and in combination with ciprofloxacin, doxycycline, and rifampin. Antimicrob Agents Chemother 37: 2333–2336 (In vivo efficacy of streptomycin, doxycycline, rifampin, ciprofloxacin, and their combination was evaluated for a Brucella melitensis experimental infection in a mouse model. Therapy failure was noted in streptomycin and ciprofloxacin treated animals. Also none of the animals receiving the streptomycin-ciprofloxacin combinations was cured.)

    Article  CAS  Google Scholar 

  23. Akova M, Gur D, Livermore DM, Kocagöz T, Akalin HE (1999) In vitro activities of antibiotics alone and in combination against Brucella melitensis at neutral and acidic PHs. Antimicro Agents Chemother 43: 1298–1300 (Azithromycin, streptomycin, and quinolones were active against Brucella melitensis at PH 7.0 but not at PH 5.0, rifampin and doxycycline retained activity at PH 5.0. Regardless of PH, azithromycin-rifampin and ofloxacin-rifampin showed less synergy than established standard combination.)

    Article  CAS  Google Scholar 

  24. Akova M, Uzun O, Akalin HE, Hayran M, Unal S, Gür D (1993) Quinolones in treatment of Human Brucellosis: Comparative trial of ofloxacin-rifampin vs. doxycycline-rifampin. Antimicrob Agents Chemother 37: 1831–1834 (A prospective randomized study comparing the efficacy of ofloxacin plus rifampin with doxycyline plus rifampin both combination given for 6 weeks against Brucellosis. Thirty patients were enrolled in each arm with relapse rates of 3.3% and 3.2% respectively.)

    Article  CAS  Google Scholar 

  25. Aglar C, Usubutun S, Turkylmaz R (1999) Ciprofloxacin and rifampin vs. doxycycline and rifampin in the treatment of Brucellosis. Eur J Clin Microbiol Infect Dis 18: 535–538 (Open randomized clinical trial comparing the efficacy of ciprofloxacin-rifampin vs. doxycycline-rifampicin both for 6 weeks in the treatment of brucellosis. Twenty (20) pateints were enrolled in each arm of the study and the relapse rate was 15% vs 10%.)

    Article  Google Scholar 

  26. Smith MD, Vinh SX, Nguyen TT, Wain J, Thung D, White NJ (1995) In vitro antimicrobial susceptibilities of strains of Y. pestis. Antimicrob Agents Chemother 39: 2153–2154 (In vitro activities of 14 antimicrobial agents were determined for 78 strains of Y. pestis. The most active antibiotics were ceftriaxone and ciprofloxacin, followed by ofloxacin and ampicillin.)

    Article  CAS  Google Scholar 

  27. Frean JA, Arntzen L, Capper T, Bryskier A, Kingman KP (1996) In vitro activities of 14 antibiotics against 100 human isolates of Yersinia pestis from a Southern African plague focus. Antimicrob Agents Chemother 40: 2646–2647 (In vitro activities of 14 antibiotics against 100 human isolates of Y. pestis. Among the injectable agents tested, cefotaxime was the most active, and among the oral agents, both levofloxacin and ofloxacin were highly active.)

    Article  CAS  Google Scholar 

  28. Russell P, Eley SM, Green M, Stagg AJ, Taylor RR, Nelson M, Beedham RI, Bell DL, Rogers D, Whittington D, Titball RW (1998) Efficacy of doxycycline and ciprofloxacin against experimental Y. pestis infection in mice. J Antimicrob Chemother 41: 301–305 (The efficacies of ciprofloxacin and doxycycline prophylaxis and therapy was assessed against experimental plague. Ciprofloxacin prophylaxis and therapy was successful for up to 24 h after challenge, but not after 48 h.)

    Article  CAS  Google Scholar 

  29. Inglesby TV, Dennis DT, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Friedlander AM, Hauer J, Koerner JF et al (2000) plague as a biological weapon: Medical and Public health management. JAMA 283: 2281–2290 (This is a consensus statement of the working group on civilian biodefense. Describes the history, epidemiology, microbiology, pathogenesis and clinical manifestations, diagnosis and therapy for plague based on an extensive review of the scientific literature.)

    Article  CAS  Google Scholar 

  30. Syrjala H, Schildt R, Raisainen S (1991) In vitro susceptibility of Francisella tularensis to fluroquinolones, treatment of tularemia with norfloxacin, ciprofloxacin Eur JClin Microbial Infect Dis (1991) 10: 68–70 (In vitro susceptibility was demonstrated in 10 strains of F. tularensis to ciprofloxacin, norfloxacin, ofloxacin and pefloxacin.)

    Google Scholar 

  31. Ikaheimo I, Syrjala H, Karhukorpi J, Schildt R, Koskela M (2000) In vitro susceptibility of Francisella tularensis isolated from humans and animals. J Antimicrob Chemother 46: 287–290 (The in vitro susceptibility of 38 strains fo F. tularensis was determined using E test. The quinolones examined had low MIC90s including ciprofloxacin, levofloxacin, grepafloxacin and trovafloxacin.)

    Article  CAS  Google Scholar 

  32. Limaye AP, Hooper CJ (1999) Treatment of Tularemia with fluroquinolones: Two cases and review. Clin Infect Dis 29: 922–924 (A description of two cases of acutely ill immunocompromised patients who had presumed atypical pneumonia and responded to treatment with levofloxacin. The diagnosis of tularemia confirmed in these two cases by positive blood culture, review of eight more cases of tularemia treated with quinolones with favourable clinical response was documented.)

    Article  CAS  Google Scholar 

  33. Chocarro A, Gonzalez A, Garcia I (2000) Treatment of Tularemia with ciprofloxacin. Clinical Infect Dis 31: 623 (Out of 57 cases of tularemia, 14 patients were treated with ciprofioxacin, relapse was observed in 50%. Ciprofloxacin was used as primary therapy in <42%.)

    Article  CAS  Google Scholar 

  34. Perez-Castrillon JL, Bachiller-Luque P, Martin-Luquero M, Mena-Martin FJ, Herreros V (2001) Tularemia epidemic in northwestern Spain: clinical description and therapeutic response. Clinical Infect Dis 33: 573–576 (Description of of the clinical characteristics and clinical response to an outbreak of tularemia (142 cases). The therapeutic failure rates was 22.5%. Ciprofloxacin was the antibiotic with the lowest resistance and therapeutic failure.)

    Article  CAS  Google Scholar 

  35. Johansson A, Berglund L, Gothefors L, Sjostedt A, Tamvik A (2000) Ciprofloxacin for treatment of tularemia in children. Pediatr Infect Dis J 19: 449–453 (A study on the clinical response of 12 children with ulcenoglandular tularemia to 10–14 drugs of oral ciprofioxacin. All children recovered without complications.)

    Article  CAS  Google Scholar 

  36. Swartz MN (2001) Recognition and management of Anthrax — An update. New Eng J Med 345: 1621–1626 (An extensive up-to-date review of the literature on the bacteriology, pathogenesis, epidemiology, clinical features, diagnosis and treatment of anthrax if used as a biological war agent.)

    Article  CAS  Google Scholar 

  37. Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Friedlander AM, Hayer J, McDade J, Osterholm MT, O’Toole T (1999) Anthrax as a biological weapon: Medical and Public Health Management. JAMA 281: 1735–1745 (Consensus statement made by the working group on civilian biodefense based on review of the available literature with clear guidelines on medical and public management of anthrax if used as a bioweapon.)

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Medicine and Infection Prevention and Control, King Fahad National Guard Hosptal, P.O. Box 22490, Riyadh, 11426, Saudi Arabia

    Ziad A. Memish

  2. Infection Prevention and Control, Peter Lougheed Centre, 3500-26th Avenue NE, Calgary, AB, TIY 6J4, Canada

    Manuel W. Mah

Authors
  1. Ziad A. Memish
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Manuel W. Mah
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Faculty of Medicine, The University of Manitoba, 409 Tacho Avenue, Winnipeg, Manitoba, R2H 2A6, Canada

    Allan R. Ronald

  2. Microbiology Laboratory, Mt. Sinai Hospital, 600 University Avenue, Toronto, Ontario, M5G 1X5, Canada

    Donald E. Low

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Basel AG

About this chapter

Cite this chapter

Memish, Z.A., Mah, M.W. (2003). Less usual indications: Mycobacterial, Brucella, Yersinia, Francisella and other infections. In: Ronald, A.R., Low, D.E. (eds) Fluoroquinolone Antibiotics. Milestones in Drug Therapy. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-8103-6_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-0348-8103-6_14

  • Published:

  • Publisher Name: Birkhäuser, Basel

  • Print ISBN: 978-3-0348-9437-1

  • Online ISBN: 978-3-0348-8103-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation